In this study, we employed CRISPR-Cas9 technology to generate isogenic
induced pluripotent stem cells (iPSCs) with a corrected GLP1-R gene, serving as
a control to patient-derived iPSCs harboring GLP1-R mutations.
We tested these isogenic iPSCs and their pluripotency potential by measuring the
expression of two common pluripotency markers Tra-1-81 and Tra-1-60.
Moreover, we performed quantitative PCR (qPCR) experiments to measure the
transcription levels of the GLP1-R gene in isogenic and mutant iPSC clones.
Our findings revealed significant differences in GLP1-R transcription levels and
mRNA structures between the mutant and isogenic clones. These insights
contribute to a better understanding of the mosaic nature of mutant iPSCs and the
functional consequences of GLP1-R mutations.
|Date of Award||Jul 2023|
|Original language||English (US)|
- Biological, Environmental Sciences and Engineering
|Supervisor||Mo Li (Supervisor)|